Drug Profile
DRGT 96
Alternative Names: DRGT-96Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Druggability Technologies
- Developer Tavanta Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Prostate cancer in Hungary (unspecified route)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Prostate-cancer in Hungary
- 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics